Anticoagulation in Device-Detected Atrial Fibrillation—Uncertainty and Heterogeneity in Value

By
Hanxuan Yu
Jinyi Zhu
June 8, 2026
0 min

Jama Network Open

Overview

Recent trials indicate that anticoagulation in device-detected atrial fibrillation (AF) may reduce stroke risk but increases major bleeding. The economic evaluation suggests that routine anticoagulation may not represent high-value care, particularly in patients with lower stroke risk.

Background

Atrial fibrillation is a significant risk factor for stroke, yet management strategies for subclinical AF detected by devices remain uncertain. Recent randomized trials have begun to clarify the role of direct oral anticoagulants (DOACs) in these cases, highlighting the need for careful consideration of both benefits and risks. Understanding the economic implications of anticoagulation in device-detected AF is crucial for optimizing patient care.

Data Highlights

No numerical data available.

Key Findings

Pooled results from ARTESiA and NOAH-AFNET 6 trials showed a 32% reduction in ischemic stroke risk with DOACs but increased major bleeding risk (risk ratio, 1.62).
Subgroup analysis indicated that patients with a CHA2DS2-VASc score >4 may benefit more from DOACs, with a higher absolute reduction in stroke risk.
The 2024 European Society of Cardiology guidelines recommend considering DOACs for selected patients with high stroke risk and no major bleeding risk factors.
A cost-effectiveness analysis found that DOACs provided minimal QALY gains at high incremental costs for patients with lower CHA2DS2-VASc scores.
For patients with CHA2DS2-VASc scores greater than 4, DOAC therapy showed a favorable ICER of €44,595/QALY, suggesting potential benefits may outweigh risks.
Economic evaluations highlight the importance of baseline stroke risk and treatment costs in determining the value of anticoagulation for device-detected AF.

Clinical Implications

Clinicians should carefully assess stroke risk using the CHA2DS2-VASc score when considering anticoagulation for patients with device-detected AF. The economic implications of treatment decisions should also be taken into account, particularly in patients with lower stroke risk.

Conclusion

The management of device-detected AF requires a nuanced approach that balances the benefits of anticoagulation against the risks and costs involved. Further research is needed to refine treatment strategies in this population.